Pinatuzumab
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin. Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Product Specifications
CAS Number
1639820-81-7
UNSPSC
12352203
Target
CD22; Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pinatuzumab.html
Purity
96.98
Solubility
10 mM in DMSO
Smiles
[Pinatuzumab]
Molecular Weight
(146.69 kDa)
References & Citations
[1]Wei, L., Xiang, Z., & Zou, Y. (2023) . The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy. International journal of molecular sciences, 24 (24), 17545. |[2]Yip, V., et al., (2024) . Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species. Xenobiotica; the fate of foreign compounds in biological systems, 54 (8), 511–520.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Benz[a]anthracene-7-acetic Acid-13C2](https://cdn.genprice.uk/products/572/8040070560709/imageurl/trc-b183572-5mg.webp)
BNUB1260-500 1x 500 µL
Carcinoembryonic Antigen (CEA) / CD66 (C66/1260), 0.2mg/mL
Sign In for Pricing
View Details 
